An interventional study of 20% High Dose Albumin and Standard Medical Treatment in Liver Cirrhosis and Spontaneous Bacterial Peritonitis, sponsored by Institute of Liver and Biliary Sciences, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India — 15 open to participants now, 15 under way, 1 of them phase 3. Liver Cirrhosis · Institute of Liver and Biliary Sciences, India.
Among the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, this one is the 6th largest by planned enrollment of the 42 interventional ones that give a count, is one of 12 that started in 2023, is one of 40 with no phase, reaches primary completion later than 4 of the 14 other live ones, and was the 36th registered.
1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.
Browse Liver Cirrhosis studies →15 of the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–75
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–70
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–70
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–80
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 100 across the 42 interventional studies, 56 across the 11 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institute of Liver and Biliary Sciences, India is the lead sponsor of 303 studies on the registry; 88 are open to participants now.
3 of the studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07002827Institute of Liver and Biliary Sciences, IndiaEffect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis. | 2026-12-30 |
| NCT07433881Institute of Liver and Biliary Sciences, IndiaSerosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis | 2027-02-27 |
| NCT07465471Institute of Liver and Biliary Sciences, IndiaCarvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The role of Albumin in prevention and Treatment of Acute Kidney Injury (AKI) in patients with Spontaneous Bacterial Peritonitis (SBP) who are at high risk of AKI development has been clearly defined, which decreases the morbidity and mortality. However the conventional dose recommended by the guidelines is usually not tolerated by the Indian population. Investigator propose that the low dose is as beneficial as the standard dose in patients with high risk SBP in the prevention/progression of renal dysfunction in cirrhotic patients with high risk spontaneous bacterial peritonitis. If confirmed, these results could support a significant cost reduction in the management of ascites in cirrhotic patients and decrease the side effects of the volume overload in the patient of the cirrhosis.
Hypothesis Alternate Hypothesis: Low dose albumin is as effective as conventional dose albumin in cirrhosis with high risk SBP patients having AKI development or progression by day 4.
Aim:-To compare the efficacy and safety of low dose albumin with conventional dose albumin in AKI development or progression in patients with cirrhosis and high risk spontaneous bacterial peritonitis.
Study population: Patients of age > 18 years of age with cirrhosis of liver who are admitted in ward/ICU diagnosed with high risk SBP.
Study design: Randomized controlled trial Study period:1.5year Sample size: 300 (150 cases in each group) Assuming that the rate of AKI development in conventional dose albumin group - 10% and low dose albumin group 15%, Power- 80%, Alpha- 10% ONE SIDED, Non inferiority limit- 5, cases needed to enroll are 270, further assuming 10% dropout, investigator decided to enroll total 300 cases, randomly allocated with 150 cases in each arm by block randomization method with Block size of 10 Cases will be randomly allocated in 2 groups by block randomization method with block size taken as 10.
STATISTICAL ANALYSIS:
Continuous variables- Mean +/- SD Categorical variables as percentages (%) or Frequencies Student t test will be applied in continuous data compared with two groups Survival analysis like Cox-Regression model and Kaplan-Meir plots will be plotted to find the possible factors responsible for mortality Besides these, Intent to treat (ITT) and Per Protocol (PP) will be done at the time of data analysis.
Adverse effects:
Patients receiving Albumin may experience Nausea, Vomiting, Fever with chills, dyspnea Wheezing, Volume overload, Anaphylactic reaction
Stopping rule of study:
Adverse reaction to drug Cardiopulmonary compromise
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg body weight (Maximum 100g)on day 3 along with standard medical therapy.
Biological: 20% High Dose Albumin · Other: Standard Medical Treatment
Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.
Other: Standard Medical Treatment · Biological: 20% Reduced Dose Albumin
A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy. Duration of albumin over 24 hours.
Standard Medical Treatment
B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy. Duration of albumin over 24 hours.
Proportion of patients developing new AKI or having progression of AKI by day 4.
Time frame: Day 4
Resolution of Spontaneous Bacterial Peritonitis by day 5
Resolution is defined as decrease in ascitic fluid PMN \> 25% from baseline
Time frame: Day 5
Change on Serum Ascites Albumin Gradient (SAAG) in both the groups.
Time frame: Day 5
Change in cell count (PMN) in both groups.
Time frame: Day 5
Changes in PRA levels from baseline to day 7
Time frame: day 7
Changes in TNF-alpha levels from baseline to day 7
Time frame: day 7
Changes in IL-6 levels from baseline to day 7
Time frame: day 7
Changes in endotoxin levels from baseline to day 7
Time frame: day 7
Changes in renal resistive index from baseline to day 7
Time frame: day 7
Number of patients with development of complications in both groups
Time frame: 90 days
Number of Participants with changes in ProBNP from baseline to day 4 or if shortness of breath occurs
Time frame: Day 4
Number of Participants with changes in vWF-Ag from baseline to day 4
Time frame: Day 4
Number of patients expired in both the groups
Time frame: Day 7
Number of patients expired in both the groups
Time frame: Day 28
Number of patients expired in both the groups
Time frame: Day 90
Duration of hospital stay
Time frame: 90 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 14 months is below that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Liver and Biliary Sciences, India →